viernes, 30 de noviembre de 2018

Ewing Sarcoma Treatment (PDQ®)—Health Professional Version - National Cancer Institute

Ewing Sarcoma Treatment (PDQ®)—Health Professional Version - National Cancer Institute

Ewing Sarcoma Treatment (PDQ®)—Patient Version - National Cancer Institute

Sarcoma de Ewing (PDQ®)—Versión para pacientes - National Cancer Institute

Sarcoma de Ewing (PDQ®)—Versión para profesionales de salud - National Cancer Institute



National Cancer Institute



Ewing Sarcoma Treatment (PDQ®)–Health Professional Version

Changes to This Summary (11/12/2018)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Added pathologic fracture as a pretreatment prognostic factor for Ewing sarcoma. Also added text to state that a single-institution retrospective analysis of 78 patients with Ewing sarcoma suggested that pathologic fracture at initial presentation was associated with inferior event-free survival and overall survival (cited Schlegel et al. as reference 38 and level of evidence 3iiA).
Revised Table 3 to include high-dose chemotherapy with stem cell support as a treatment option for recurrent Ewing sarcoma.
Revised text to state that investigators concluded that patients who are anticipated to have suboptimal surgery should be considered for definitive radiation therapy or receive full-dose radiation therapy.
Revised text to state that the improvement was greater in patients who had large tumors and were assessed to have 100% necrosis than in patients who were assessed to have 90% to 100% necrosis.
The High-Dose Chemotherapy With Stem Cell Support for Ewing Sarcoma subsection was renamed from High-Dose Therapy With Stem Cell Rescue for Ewing Sarcoma.
Revised text to state that when no surgical resection is performed, radiation therapy is generally administered in fractionated doses totaling approximately 55.8 Gy to the prechemotherapy tumor volume.
Added high-dose chemotherapy with stem cell support as a treatment option for recurrent Ewing sarcoma.
Added text to state that several retrospective studies have demonstrated the activity of temozolomide and irinotecan in patients with recurrent Ewing sarcoma (cited Palmerini et al. as reference 15).
Added text about the results of the largest retrospective multicenter study of the combination of temozolomide and irinotecan in patients with recurrent and primary refractive Ewing sarcoma.
Added High-dose chemotherapy with stem cell support as a new subsection heading.
This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.
  • Updated: November 12, 2018

No hay comentarios:

Publicar un comentario